방사선종양학

본문글자크기
  • [Radiother Oncol.] Mapping patterns of locoregional recurrence following contemporary treatment with radiation therapy for breast cancer: A multi-institutional validation study of the ESTRO consensus guideline on clinical target volume.

    [Radiother Oncol.] Mapping patterns of locoregional recurrence following contemporary treatment with radiation therapy for breast cancer: A multi-institutional validation study of the ESTRO consensus guideline on clinical target volume.

    연세의대 / 장지석, 이정심, 김용배*

  • 출처
    Radiother Oncol.
  • 등재일
    2017 Oct 16.
  • 저널이슈번호
    pii: S0167-8140(17)32617-8. doi: 10.1016/j.radonc.2017.09.031. [Epub ahead of print]
  • 내용

    바로가기  >

    Abstract

    BACKGROUND AND PURPOSE:

    To validate the ESTRO guideline on clinical target volume (CTV) delineation for breast cancer using a multi-centre dataset.

     

    MATERIALS AND METHODS:

    Patients with axial imaging of gross locoregional recurrence (LRR) were identified from 10 participating institutions. All patients received RT, albeit not to all regional node. The location of LRR was transferred to the corresponding area on representative axial computed tomography images and compared with ESTRO-CTV.

     

    RESULTS:

    The locations of LRRs in 234 patients with 337 recurrence lesions were mapped. The ESTRO-CTV encompassed 97.6% of all LRRs, except in lymph node level 4 and the pectoralis muscle. Although 8.8% of level 4 failures occurred outside the ESTRO-CTV, cranial to the subclavian artery, all nodes were located within 6 mm cranially. Another 20% occurred posterolateral to anterior scalene muscles; however, 11/16 cases had simultaneous multiple lymph node recurrences, and 8/16 initially had N2-3 tumours. Local recurrence at the pectoralis muscle was prominent in patients undergoing mastectomy but not breast-conservation surgery (28% vs. 2.9%, P = .001).

     

    CONCLUSIONS:

    Our mapping data demonstrated that the ESTRO-CTV, with some considerations, successfully encompassed most LRRs in patients undergoing contemporary management, thus validating ESTRO-CTV to be valuable for highly conformal radiation therapy techniques.​

     


    Fig. 1. Overview of locoregional recurrence locations on the anteroposterior (AP) view, in relation to the European Society for Radiotherapy and Oncology (ESTRO)-clinical target volume (CTV; blue) and the Radiation Therapy Oncology Group (RTOG)-CTV. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)​  

    Author information

    Chang JS1, Lee J2, Chun M3, Shin KH4, Park W5, Lee JH6, Kim JH7, Yoon WS8, Lee IJ9, Kim J10, Park HL11, Kim YB12.

    Department of Radiation Oncology, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea.

    Department of Radiation Oncology, Inha University Hospital, Incheon, Republic of Korea.

    Department of Radiation Oncology, Ajou University School of Medicine, Suwon, Republic of Korea.

    Department of Radiation Oncology, Seoul National University College of Medicine, Seoul, Republic of Korea.

    Department of Radiation Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.

    Department of Radiation Oncology, St. Vincent's Hospital, College of Medicine, The Catholic University of Korea, Suwon, Republic of Korea.

    Department of Radiation Oncology, Dongsan Medical Center, Keimyung University School of Medicine, Daegu, Republic of Korea.

    Department of Radiation Oncology, Ansan Hospital, Korea University Medical Center, Ansan, Republic of Korea.

    Department of Radiation Oncology, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea.

    10 Department of Radiation Oncology, Cheil General Hospital, Dankook University College of Medicine, Seoul, Republic of Korea.

    11 Department of Radiation Oncology, Presbyterian Medical Center, Jeonju, Republic of Korea.

    12 Department of Radiation Oncology, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea. Electronic address: ybkim3@yuhs.ac. 

  • 연구소개
    최근 들어 유방암에서 방사선 치료는 과거의 2차원 통상 방사선 치료 (2D-conventional RT)에서 벗어나 3차원 입체조형치료 혹은 세기조절방사선치료라는 정밀한 치료기법이 사용되고 있고, 이에 따라 유방암에서 방사선 치료 용적 (target volume)의 중요성이 대두되고 있습니다. 기존에 가장 많이 사용되던 RTOG 치료용적 가이드라인은 주로 국소진행성 유방암을 대상으로 만들어진 반면, 최근에 발표된 ESTRO 가이드라인은 주로 조기 유방암을 대상으로 만들어졌다. 이러한 가이드라인은 전문가집단의 합의에 의해 제안된 것이므로 실제 재발 양상과 3차원적 위치 확인을 통한 정당성 입증이 필요합니다. 본 연구는 RTOG/ESTRO 가이드라인의 정당성을 확인하기 위하여 다기관 (10개) 공동연구를 진행하였고, 조기 유방암의 국소영역 재발은 대부분 ESTRO 가이드라인 치료 용적으로 예방이 가능하다는 정당성을 확인하였습니다. 그 외에 치료용적을 환자 개개인에 따라 조절해야 되는 임상적 상황에 대해 고찰 하였고, 이러한 결과는 유방암 방사선 치료에 있어서 유용한 정보를 제공할 것이라 생각합니다.
  • 편집위원

    ESTRO에서 제시한 유방암 CTV guideline에 대해서 국내 대규모 환자들 데이터로 안정성을 validation 했다는 점에서 큰 의미가 있는 것 같습니다. 국내 유방암 환자의 방사선치료의 표준화에도 많은 기여를 할 것으로 생각됩니다.

    2017-11-03 08:58:12

  • 덧글달기
    덧글달기
       IP : 52.14.121.242

    등록